[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Al-Barrag A, Al-Shaer M, Al-Matary N, Al-Hamdani M: 5-Fluorouracil for the treatment of intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva, and cornea. Clin Ophthalmol; 2010;4:801-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-Fluorouracil for the treatment of intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva, and cornea.
  • OBJECTIVE: To evaluate the efficacy and risks of complications of pulse dosing of topical 5-fluorouracil (5-FU) in the treatment of corneal intraepithelial neoplasia (CIN), and conjunctival squamous cell carcinoma (SCC).
  • PARTICIPANTS: Fifteen patients with histological evidence CIN or SCC of the conjunctiva and cornea were identified by tumor biopsy.
  • METHODS: All patients clinically evident of CIN, or SCC were evaluated, with maximum 30 months of follow-up were treated with pulsed dosing of 1% 5-FU.
  • Treatment cycles were defined as four times per day for 4 days using the medication followed by 30 days without medication.
  • The number of initial treatment was six cycles.
  • Excision biopsy proved seven cases as CIN, and eight cases as locally invasive SCC.
  • Additional chemotherapy was given after the initial treatment cycles, only for one case.
  • CONCLUSIONS: Adjuvant 1% topical 5-FU appears to be effective in the prevention of recurrence of conjunctival or corneal CIN and SCC after excision biopsy.
  • It is well-tolerated and an effective method of treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 2001 Jun;108(6):1093-8 [11382635.001]
  • [Cites] Cornea. 2009 Aug;28(7):821-4 [19574900.001]
  • [Cites] Am J Ophthalmol. 2002 May;133(5):601-6 [11992855.001]
  • [Cites] Surv Ophthalmol. 2004 Jan-Feb;49(1):3-24 [14711437.001]
  • [Cites] Ophthalmology. 2004 Sep;111(9):1747-54 [15350332.001]
  • [Cites] Am J Ophthalmol. 1989 Apr 15;107(4):337-40 [2929703.001]
  • [Cites] Doc Ophthalmol. 1986 Dec 30;64(1):31-42 [3582100.001]
  • [Cites] Ophthalmology. 1986 Feb;93(2):176-83 [3951824.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1985 Apr;26(4):580-3 [3980172.001]
  • [Cites] Am J Ophthalmol. 1984 May;97(5):547-59 [6720832.001]
  • [Cites] Am J Ophthalmol. 1983 Mar;95(3):359-63 [6829682.001]
  • [Cites] Surv Ophthalmol. 1995 May-Jun;39(6):429-50 [7660300.001]
  • [Cites] Arch Ophthalmol. 1994 Sep;112(9):1145-6 [8085957.001]
  • [Cites] Am J Ophthalmol. 1994 Feb 15;117(2):164-8 [8116744.001]
  • [Cites] Br J Ophthalmol. 1993 Nov;77(11):751-3 [8280698.001]
  • [Cites] Arch Ophthalmol. 1996 Oct;114(10):1261-4 [8859090.001]
  • [Cites] Ophthalmology. 1997 Mar;104(3):485-92 [9082277.001]
  • [Cites] Ophthalmology. 1995 Sep;102(9):1338-44 [9097771.001]
  • [Cites] Arch Ophthalmol. 1997 Jun;115(6):808-15 [9194740.001]
  • [Cites] Ophthalmology. 1997 Dec;104(12):2085-93 [9400769.001]
  • [Cites] Arch Ophthalmol. 1997 Dec;115(12):1600-1 [9400803.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):303-11 [9439356.001]
  • [Cites] Trans Am Ophthalmol Soc. 1976;74:154-71 [325854.001]
  • [Cites] Ophthalmologica. 1979;178(4):198-203 [481865.001]
  • [Cites] Am J Ophthalmol. 1976 Feb;81(2):198-206 [766640.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):381-3 [9439364.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):397-9 [9439368.001]
  • [Cites] Cornea. 1999 Jan;18(1):59-62 [9894938.001]
  • [Cites] Ophthalmology. 1999 Jan;106(1):91-7 [9917787.001]
  • [Cites] Arch Ophthalmol. 1999 Apr;117(4):544-5 [10206591.001]
  • [Cites] Br J Ophthalmol. 2000 Mar;84(3):268-72 [10684836.001]
  • [Cites] Ophthalmology. 2000 Dec;107(12):2190-5 [11097594.001]
  • [Cites] Ophthalmol Clin North Am. 2005 Mar;18(1):1-13, vii [15763187.001]
  • [Cites] Ophthalmology. 2002 Feb;109(2):249-52 [11825803.001]
  • (PMID = 20689797.001).
  • [ISSN] 1177-5483
  • [Journal-full-title] Clinical ophthalmology (Auckland, N.Z.)
  • [ISO-abbreviation] Clin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2915867
  • [Keywords] NOTNLM ; chemotherapy / fluorouracil / neoplasia / treatment cycles
  •  go-up   go-down


2. Khong JJ, Muecke J: Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. Br J Ophthalmol; 2006 Jul;90(7):819-22
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia.
  • AIM: To determine the complications associated with mitomycin C (MMC) in the treatment of ocular surface neoplasia.
  • METHODS: A retrospective and consecutive study of 100 eyes in 91 patients with ocular surface neoplasia treated with MMC in a single centre between November 1998 and January 2005.
  • Outcome measures included complications of MMC and the treatment required for these complications.
  • RESULTS: One to three 7 day cycles of topical MMC 0.04% four times a day were given to 59 eyes with localised corneal-conjunctival intraepithelial neoplasia (CIN), 19 eyes with diffuse CIN, six eyes with recurrent CIN, one eye with ocular surface squamous cell carcinoma, three eyes with primary acquired melanosis (PAM) with atypia, nine eyes with conjunctival malignant melanoma (MM), two eyes with sebaceous carcinoma with pagetoid spread, and one eye with recurrent atypical fibroxanthoma.
  • Nine patients had bilateral CIN.
  • 31 (34%) cases developed an allergic reaction to MMC and 14 (14%) eyes had epiphora secondary to punctal stenosis at a mean follow up period of 26.5 months.
  • CONCLUSION: In the largest study looking at complications of topical MMC in the treatment of ocular surface neoplasia, allergic reaction and punctal stenosis are relatively common.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. Drug Hypersensitivity / etiology. Eye Neoplasms / drug therapy. Mitomycin / adverse effects
  • [MeSH-minor] Adenocarcinoma, Sebaceous / drug therapy. Carcinoma in Situ / drug therapy. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Female. Follow-Up Studies. Histiocytoma, Benign Fibrous / drug therapy. Humans. Lacrimal Apparatus Diseases / chemically induced. Lacrimal Duct Obstruction / chemically induced. Male. Melanoma / drug therapy. Melanosis / drug therapy. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Ophthalmol. 1996 Oct;114(10):1261-4 [8859090.001]
  • [Cites] Cornea. 1996 Sep;15(5):537-40 [8862932.001]
  • [Cites] Ophthalmology. 1997 Dec;104(12):2085-93 [9400769.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):303-11 [9439356.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):397-9 [9439368.001]
  • [Cites] Br J Ophthalmol. 1998 May;82(5):476-9 [9713051.001]
  • [Cites] Am J Ophthalmol. 2005 Aug;140(2):325-7 [16086962.001]
  • [Cites] Allergy. 1997 Jun;52(6):687 [9226075.001]
  • [Cites] Contact Dermatitis. 2000 Feb;42(2):74-6 [10703627.001]
  • [Cites] Arch Ophthalmol. 2000 Jul;118(7):885-91 [10900099.001]
  • [Cites] Ophthalmology. 2001 May;108(5):994-5 [11320034.001]
  • [Cites] Clin Experiment Ophthalmol. 2002 Apr;30(2):94-8 [11886411.001]
  • [Cites] Am J Ophthalmol. 2002 May;133(5):601-6 [11992855.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2002 Jul;18(4):285-8 [12142762.001]
  • [Cites] Ophthalmology. 2002 Nov;109(11):2129-33 [12414427.001]
  • [Cites] Am J Ophthalmol. 2003 Aug;136(2):375-7 [12888073.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2003 May;19(3):216-24 [12918558.001]
  • [Cites] Am J Ophthalmol. 2003 Oct;136(4):746-7 [14516822.001]
  • [Cites] Am J Ophthalmol. 2004 May;137(5):950-1 [15126170.001]
  • [Cites] Br J Ophthalmol. 2004 Nov;88(11):1422-4 [15489486.001]
  • [Cites] Br J Dermatol. 1990 Feb;122(2):217-24 [2138492.001]
  • [Cites] Ophthalmology. 1992 Nov;99(11):1647-54 [1454338.001]
  • [Cites] Am J Ophthalmol. 1994 Feb 15;117(2):164-8 [8116744.001]
  • [CommentIn] Br J Ophthalmol. 2006 Jul;90(7):807-9 [16782942.001]
  • (PMID = 16672325.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  • [Other-IDs] NLM/ PMC1857172
  •  go-up   go-down


3. Huerva V, Mangues I: Treatment of conjunctival squamous neoplasias with interferon alpha 2ab. J Fr Ophtalmol; 2008 Mar;31(3):317-25
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of conjunctival squamous neoplasias with interferon alpha 2ab.
  • The classical approach to the treatment of squamous neoplasias of the ocular surface is based on surgical resection and cryotherapy.
  • Primary or adjuvant chemotherapy with mitomycin C (MMC) or 5-fluorouracil has been employed to treat these neoplasias, but severe side effects on the ocular surface have been described.
  • The experience in the treatment of conjunctiva-cornea intraepithelial neoplasia (CIN) with topical or intralesional INF alpha 2b is based on isolated cases or very short series.
  • The safety and effectiveness of INF alpha 2b in the treatment of primary and recurrent cases of CIN are described.
  • The absence of serious side effects after topical administration of INF alpha 2b leads to the recommendation of this modality of therapy for primary and recurrent cases of CIN.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Interferon-alpha / therapeutic use
  • [MeSH-minor] Administration, Topical. Fluorouracil / therapeutic use. Humans. Mitomycin / therapeutic use. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404128.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 50SG953SK6 / Mitomycin; 99210-65-8 / interferon alfa-2b; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. Esquenazi S, Fry CL, Holley E: Treatment of biopsy proved conjunctival intraepithelial neoplasia with topical interferon alfa-2b. Br J Ophthalmol; 2005 Sep;89(9):1221
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of biopsy proved conjunctival intraepithelial neoplasia with topical interferon alfa-2b.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma in Situ / drug therapy. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Interferon-alpha / administration & dosage

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 2001 Jun;108(6):1093-8 [11382635.001]
  • [Cites] Cornea. 2002 Jan;21(1):6-11 [11805499.001]
  • [Cites] Ophthalmology. 1999 Jan;106(1):91-7 [9917787.001]
  • [Cites] Ophthalmology. 1997 Mar;104(3):485-92 [9082277.001]
  • [Cites] Ophthalmology. 1986 Feb;93(2):176-83 [3951824.001]
  • (PMID = 16113387.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  • [Other-IDs] NLM/ PMC1772848
  •  go-up   go-down


5. Schechter BA, Schrier A, Nagler RS, Smith EF, Velasquez GE: Regression of presumed primary conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b. Cornea; 2002 Jan;21(1):6-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of presumed primary conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b.
  • PURPOSE: To evaluate topical interferon alpha-2b (IFNalpha2b) as a lone therapy in the treatment of primary conjunctival and corneal intraepithelial neoplasia (CIN).
  • Seven patients from three institutions, treated between February and October 1999, with presumed primary CIN lesions (clinically diagnosed by corneal specialists) were given topical IFNalpha2b drops (1 million units/mL) four to six times daily.
  • Follow-up was performed biweekly until there was complete clinical resolution of the presumed CIN lesions.
  • RESULTS: All seven eyes had complete resolution of the presumed CIN lesions after an average of 77.0 +/- 59.2 days (range, 28-188 days).
  • Side effects of treatment were limited to mild conjunctival hyperemia and follicular conjunctivitis in four (57.1%) eyes.
  • In all cases, there was total resolution of conjunctival hyperemia and follicular changes within 1 month after cessation of the medication, without additional treatment.
  • CONCLUSIONS: Topical IFNalpha2b alone may be an effective treatment of primary CIN.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy. Interferon-alpha / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11805499.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Ophthalmic Solutions; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


6. Yeatts RP, Engelbrecht NE, Curry CD, Ford JG, Walter KA: 5-Fluorouracil for the treatment of intraepithelial neoplasia of the conjunctiva and cornea. Ophthalmology; 2000 Dec;107(12):2190-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-Fluorouracil for the treatment of intraepithelial neoplasia of the conjunctiva and cornea.
  • OBJECTIVE: To evaluate the efficacy of pulse dosing of topical 5-fluorouracil (5-FU) in the treatment of conjunctival and corneal intraepithelial neoplasia.
  • PARTICIPANTS: Seven patients with histologic evidence of intraepithelial neoplasia were identified by conjunctival biopsy or tumor excision.
  • Topical 1% 5-FU was administered four times daily for 2 to 4 days for each cycle.
  • The number of initial treatment cycles was two to six, with the time between cycles being 30 to 45 days.
  • MAIN OUTCOME MEASURES: The presence or absence of clinically evident intraepithelial neoplasia was evaluated after each treatment interval.
  • RESULTS: Four patients remain disease free with a mean follow-up of 18.5 months (range, 7-36 months) with no additional treatment after the initial treatment cycles (mean, 3.75 cycles; range, 2-5 cycles).
  • Three patients had recurrence of disease after the initial treatment cycles.
  • Two patients were treated with additional cycles for recurrent disease (six cycles in one patient and five cycles in the other patient) and are free of disease at 20 and 21 months after treatment, respectively.
  • One patient had persistent disease despite treatment with topical 5-FU and was treated with topical mitomycin C with resolution of the disease without recurrence for 16.5 months.
  • No adverse reactions to pulse dose treatment with topical 5-FU were noted.
  • CONCLUSIONS: Pulsed dosing with 1% topical 5-FU for the treatment of conjunctival and corneal intraepithelial neoplasia, alone or as an adjunct to excision of bulky disease, is a well-tolerated and effective method of treatment.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy. Fluorouracil / therapeutic use
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Humans. Male. Ophthalmic Solutions / therapeutic use. Prospective Studies

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11097594.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Ophthalmic Solutions; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Zaki AA, Farid SF: Management of intraepithelial and invasive neoplasia of the cornea and conjunctiva: a long-term follow up. Cornea; 2009 Oct;28(9):986-8
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of intraepithelial and invasive neoplasia of the cornea and conjunctiva: a long-term follow up.
  • PURPOSE: The aim of this work is to report the long-term results of using immunotherapy for the management of cornea and conjunctiva intraepithelial neoplasia and squamous cell carcinoma after surgical excision of the neoplasm.
  • METHODS: Ten eyes of 10 patients with cornea and conjunctiva intraepithelial neoplasia or squamous cell carcinoma had wide surgical excisions of the neoplasm after evaluation of the level of corneal involvement using ultrasound biomicroscopy.
  • All eyes received topical cyclosporine A (0.05%) and topical mitomycin C (0.01%) 4 times daily for 12 weeks after surgery.
  • Epithelial toxicity (punctate keratopathy) occurred in 3 eyes, ocular irritation and mild conjunctival hyperemia in 5 eyes, and lid toxicity in 2 cases during the treatment with mitomycin C.
  • There were no serious complications that necessitated stopping the treatment.
  • CONCLUSION: During a 2-year follow-up period, the use of topical cyclosporine A (0.05%) combined with mitomycin C (0.01%) as an adjunctive treatment after surgical excision in cornea and conjunctiva intraepithelial neoplasia and squamous cell carcinoma was found to prevent tumor recurrence, especially in extensive lesions, when surgical excision cannot ensure a tumor-free margin.
  • [MeSH-major] Carcinoma in Situ / therapy. Carcinoma, Squamous Cell / therapy. Conjunctival Neoplasms / therapy. Corneal Diseases / therapy. Eye Neoplasms / therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Cyclosporine / administration & dosage. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Male. Mitomycin / administration & dosage. Neoplasm Invasiveness. Ophthalmologic Surgical Procedures. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cornea. 2012 Apr;31(4):465 [22314824.001]
  • [CommentIn] Cornea. 2011 Apr;30(4):486; author reply 486-7 [21107255.001]
  • (PMID = 19724215.001).
  • [ISSN] 1536-4798
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


8. Huerva V, Mateo AJ, Mangues I, Jurjo C: Short-term mitomycin C followed by long-term interferon alpha2beta for conjunctiva-cornea intraepithelial neoplasia. Cornea; 2006 Dec;25(10):1220-3
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-term mitomycin C followed by long-term interferon alpha2beta for conjunctiva-cornea intraepithelial neoplasia.
  • PURPOSE: To report a case of extensive conjunctiva-cornea intraepithelial neoplasia (CIN) treated topically with mitomycin C (MMC) and interferon (INF)-alpha2beta without surgical resection.
  • RESULTS: : An 82-year-old woman showed an extensive gelatinous red mass in the bulbar conjunctiva with invasion into the caruncle, inferior fornix, and tarsal conjunctiva and extending for 270 degrees of the corneal surface.
  • A diagnosis of CIN was made by surgical biopsy.
  • A conservative treatment strategy was used with 2 cycles of topical MMC (0.02%), followed by INF-alpha2beta eye drops at a dose of 1 million IU/mL, 4 times a day until tumor disappearance.
  • Total resolution was noted after 75 days of treatment with INF, with no clinical evidence of limbal stem cell deficiency.
  • After 1 year of monitoring, no signs of CIN recurrences were observed.
  • CONCLUSION: MMC (0.02%), followed by INF-alpha2beta (1 million IU/mL) 4 times a day, is an effective treatment against highly extensive CIN, in cases where surgical resection with safety margins is unfeasible.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy
  • [MeSH-minor] Administration, Topical. Aged, 80 and over. Biopsy. Eye Neoplasms / drug therapy. Eye Neoplasms / pathology. Female. Humans. Interferon-alpha / administration & dosage. Mitomycin / administration & dosage. Recombinant Proteins. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17172902.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 50SG953SK6 / Mitomycin; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


9. Dogru M, Erturk H, Shimazaki J, Tsubota K, Gul M: Tear function and ocular surface changes with topical mitomycin (MMC) treatment for primary corneal intraepithelial neoplasia. Cornea; 2003 Oct;22(7):627-39
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tear function and ocular surface changes with topical mitomycin (MMC) treatment for primary corneal intraepithelial neoplasia.
  • PURPOSE: To evaluate the tear function and ocular surface alterations in patients with primary CIN before and after treatment with topical mitomycin (MMC).
  • PATIENTS AND METHODS: We describe seven patients with unilateral CIN treated with 0.04% topical MMC three times daily until full eradication of the lesion.
  • The patients underwent tear and ocular surface examinations including Cochet-Bonnet corneal sensitivity measurements, tear film break-up time (BUT), Schirmer test, and Rose-Bengal staining before, at the time of resolution of the CIN, and at the final follow-up.
  • Conjunctival impression cytology was performed before treatment and at the last visit.
  • RESULTS: The mean pretreatment corneal sensitivity was 30.3 +/- 7.4 mm and improved to 55 +/- 5 mm at the final visit (P < 0.05).
  • MMC-induced cytologic changes were seen to persist long after cessation of treatment in some patients.
  • CONCLUSION: We found 0.04% topical MMC treatment tid until full eradication to be effective in the management of CIN.
  • The ocular surface disease of CIN was characterized by disturbance of tear film stability, goblet cell loss, and increased squamous metaplasia in all patients.
  • Impression cytology proved useful in attaining the diagnosis of CIN, evaluating the effect of treatment, and showing MMC-related long-term changes on the ocular surface.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Conjunctiva / pathology. Corneal Diseases / drug therapy. Corneal Diseases / pathology. Eye Neoplasms / drug therapy. Eye Neoplasms / pathology. Mitomycin / administration & dosage. Tears / metabolism
  • [MeSH-minor] Administration, Topical. Aged. Cell Count. Cornea / physiopathology. Epithelial Cells / pathology. Female. Fluorescent Dyes. Goblet Cells / pathology. Humans. Male. Metaplasia. Middle Aged. Prospective Studies. Rose Bengal. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14508259.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Fluorescent Dyes; 1ZPG1ELY14 / Rose Bengal; 50SG953SK6 / Mitomycin
  •  go-up   go-down


10. Di Pascuale MA, Espana EM, Tseng SC: A case of conjunctiva-cornea intraepithelial neoplasia successfully treated with topical mitomycin C and interferon alfa-2b in cycles. Cornea; 2004 Jan;23(1):89-92
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of conjunctiva-cornea intraepithelial neoplasia successfully treated with topical mitomycin C and interferon alfa-2b in cycles.
  • PURPOSE: To report a case of conjunctiva-cornea intraepithelial neoplasia (CCIN) treated with topical mitomycin C (MMC) and interferon alfa-2b in cycles.
  • The diagnosis was confirmed by impression cytology and treated in cycles with topical 0.02% MMC for 14 days in the first cycle, 12 days in the second cycle, and 3 days in the third cycle followed by topical interferon alfa-2b 1 x 106 U/mL for 11 days.
  • CONCLUSIONS: After differentiation from a persistent corneal epithelial defect and limbal stem cell deficiency by dye staining and impression cytology, the patient in this case of CCIN was successfully treated with topical MMC and interferon alfa-2b in cycles.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Interferon-alpha / administration & dosage. Mitomycin / administration & dosage
  • [MeSH-minor] Administration, Topical. Drug Administration Schedule. Female. Humans. Middle Aged. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14701965.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 50SG953SK6 / Mitomycin; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


11. Huerva V, Sánchez MC, Mangues I: Tumor-volume increase at beginning of primary treatment with topical interferon alpha 2-beta in a case of conjunctiva-cornea intraepithelial neoplasia. J Ocul Pharmacol Ther; 2007 Apr;23(2):143-5
MedlinePlus Health Information. consumer health - Corneal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-volume increase at beginning of primary treatment with topical interferon alpha 2-beta in a case of conjunctiva-cornea intraepithelial neoplasia.
  • AIMS: The aim of this study was to report on the effectiveness and tumor side effects of topical interferon (INF) alpha 2-beta in a case of conjunctiva-cornea intraepithelial neoplasia (CIN) of a patient that rejected any surgical procedure.
  • RESULTS: An 81-year-old man with a history of neoplasies of the colon and prostate and anticoagulant treatment was referred for treatment of an ocular surface neoplasia on his left eye.
  • Pathognomonic signs of CIN were present.
  • A regimen of topical INF alpha 2-beta 4 times daily was administered.
  • An increase in tumor volume of 25% was observable 15 days after the beginning of therapy.
  • The treatment continued with follow-ups every 15 days.
  • Complete regression of the CIN was observable after 60 days of therapy.
  • CONCLUSIONS: Topical INF alpha 2-beta is a valid choice for the treatment of CIN in patients for whom surgery is not possible.
  • The increase of tumor volume at the beginning of therapy does not require the suspension of treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Interferon-alpha / therapeutic use
  • [MeSH-minor] Administration, Topical. Aged, 80 and over. Eye Neoplasms / drug therapy. Humans. Male. Ophthalmic Solutions. Recombinant Proteins. Remission Induction. Tumor Burden / drug effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17444802.001).
  • [ISSN] 1080-7683
  • [Journal-full-title] Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
  • [ISO-abbreviation] J Ocul Pharmacol Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Ophthalmic Solutions; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


12. Papandroudis AA, Dimitrakos SA, Stangos NT: Mitomycin C therapy for conjunctival-corneal intraepithelial neoplasia. Cornea; 2002 Oct;21(7):715-7
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitomycin C therapy for conjunctival-corneal intraepithelial neoplasia.
  • PURPOSE: To evaluate the efficacy and safety of topical mitomycin C (MMC) for conjunctival-corneal intraepithelial neoplasia (CCIN).
  • The size of the CCIN before and after the treatment and ophthalmic mitomycin C related complications were evaluated.
  • The complications of mitomycin C included a mild tearing and a slight conjunctival hyperemia that resolved 7 days after the end of the therapy.
  • CONCLUSION: Multiple applications of mitomycin C could be an effective treatment for selected cases of CCIN.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy. Mitomycin / therapeutic use. Neoplasms, Second Primary / drug therapy

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12352093.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


13. Rozenman Y, Frucht-Pery J: Treatment of conjunctival intraepithelial neoplasia with topical drops of mitomycin C. Cornea; 2000 Jan;19(1):1-6
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of conjunctival intraepithelial neoplasia with topical drops of mitomycin C.
  • PURPOSE: To evaluate the efficacy and risks of complications of topical mitomycin C (MMC) for small-size conjunctival intraepithelial neoplasia (CIN).
  • METHODS: Eight patients with clinically diagnosed CIN <8 mm were included in the study.
  • Patients received topical drops of MMC, 0.02-0.04%, 4 times daily for 14 days.
  • Retreatment was done when lesions were not eliminated or recurred after the first treatment.
  • After retreatment, the lesions were eradicated in four patients, whereas in one patient, the treatment failed, and the lesion was surgically excised.
  • The complications of MMC use included mild conjunctival hyperemia in two patients and mild allergy in one patient, which resolved after discontinuation of the treatment.
  • CONCLUSION: Application of topical MMC is an effective treatment for most but not all cases of small-size CIN.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Mitomycin / therapeutic use
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Leukoplakia / drug therapy. Leukoplakia / pathology. Male. Middle Aged. Ophthalmic Solutions / administration & dosage. Ophthalmic Solutions / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10631999.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Ophthalmic Solutions; 50SG953SK6 / Mitomycin
  •  go-up   go-down


14. Pournaras JA, Chamot L, Uffer S, Zografos L: Conjunctival intraepithelial neoplasia in a patient treated with tacrolimus after liver transplantation. Cornea; 2007 Dec;26(10):1261-2
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conjunctival intraepithelial neoplasia in a patient treated with tacrolimus after liver transplantation.
  • PURPOSE: To report a case of conjunctival intraepithelial neoplasia in a patient treated with tacrolimus after liver transplantation for hepatic carcinoma.
  • RESULTS: A 70-year-old man presented with a conjunctival intraepithelial neoplasia that developed on the site of a preexisting pterygium.
  • CONCLUSIONS: We describe a case of intraepithelial conjunctival neoplasia in a patient treated with systemic tacrolimus.
  • [MeSH-major] Carcinoma in Situ / etiology. Conjunctival Neoplasms / etiology. Immunosuppressive Agents / therapeutic use. Liver Transplantation. Tacrolimus / therapeutic use
  • [MeSH-minor] Aged. Antibiotics, Antineoplastic / therapeutic use. Combined Modality Therapy. Humans. Liver Neoplasms / drug therapy. Male. Mitomycin / therapeutic use

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043187.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Immunosuppressive Agents; 50SG953SK6 / Mitomycin; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


15. Prabhasawat P, Tarinvorakup P, Tesavibul N, Uiprasertkul M, Kosrirukvongs P, Booranapong W, Srivannaboon S: Topical 0.002% mitomycin C for the treatment of conjunctival-corneal intraepithelial neoplasia and squamous cell carcinoma. Cornea; 2005 May;24(4):443-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical 0.002% mitomycin C for the treatment of conjunctival-corneal intraepithelial neoplasia and squamous cell carcinoma.
  • PURPOSE: To demonstrate the efficacy of topical 0.002% mitomycin C (MMC) as an adjunctive and alternative treatment in primary and recurrent conjunctival-corneal intraepithelial neoplasia (CCIN) and squamous cell carcinoma (SCC).
  • All cases were treated with topical 0.002% MMC 4 times daily.
  • The tumor size pre- and post-treatment, clinical response, and ocular complications were evaluated.
  • Before MMC treatment, 6 eyes (85.7%) had recurrences after surgical excision.
  • MMC 0.002% 4 times daily was applied for a period of 5.4 +/- 4.4 weeks (range, 2-14).
  • Side effects of MMC therapy included ocular irritation, mild conjunctival hyperemia, and punctate keratopathy.
  • The mean follow-up time was 30.7 +/- 15 months (range, 2-52) with no evidence of clinical recurrence in any case.
  • CONCLUSIONS: Topical 0.002% MMC showed a favorable outcome as an adjunctive and alternative treatment of CCIN and SCC with regression of primary and recurrent tumors.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Carcinoma in Situ / drug therapy. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy. Mitomycin / administration & dosage
  • [MeSH-minor] Administration, Topical. Adult. Aged. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15829803.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


16. Karp CL, Moore JK, Rosa RH Jr: Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b. Ophthalmology; 2001 Jun;108(6):1093-8
MedlinePlus Health Information. consumer health - Corneal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b.
  • OBJECTIVE: To evaluate the role of topical interferon alfa-2b (IFNalpha2b) in the treatment of conjunctival and corneal intraepithelial neoplasia (CIN).
  • PARTICIPANTS: Five patients with histologically proven CIN or recurrences of proven CIN were studied prospectively.
  • INTERVENTION: After histologic confirmation, patients were given topical recombinant IFNalpha2b (INTRON A, Schering Plough, Kenilworth, NJ) 1 million IU/ml four times a day.
  • RESULTS: All patients had complete resolution of the CIN lesion on IFNalpha2b.
  • The mean time to clinical resolution was 11.6 weeks (range, 4-22 weeks).
  • One patient had a clinical recurrence of his corneal CIN 1 year after tumor resolution.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Interferon-alpha / therapeutic use
  • [MeSH-minor] Administration, Topical. Adult. Aged. Eye Neoplasms / drug therapy. Eye Neoplasms / pathology. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Ophthalmic Solutions. Recombinant Proteins. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11382635.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Ophthalmic Solutions; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


17. Dudney BW, Malecha MA: Limbal stem cell deficiency following topical mitomycin C treatment of conjunctival-corneal intraepithelial neoplasia. Am J Ophthalmol; 2004 May;137(5):950-1
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limbal stem cell deficiency following topical mitomycin C treatment of conjunctival-corneal intraepithelial neoplasia.
  • PURPOSE: To report a case of conjunctival-corneal intraepithelial neoplasia (CCIN) in an elderly African American patient treated with topical mitomycin C and the subsequent complication of limbal stem cell deficiency.
  • RESULTS: The CCIN regressed completely following mitomycin C therapy.
  • Three months later, the patient developed recurrent nonhealing epithelial defects in the right cornea.
  • CONCLUSIONS: Conjunctival-corneal intraepithelial neoplasia may occur in the African American population.
  • Although MMC is effective in eradicating CCIN, a limbal stem cell deficiency may complicate the treatment.
  • [MeSH-major] Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / chemically induced. Corneal Diseases / drug therapy. Epithelium, Corneal / drug effects. Mitomycin / adverse effects. Stem Cells / drug effects
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / adverse effects. Eye Neoplasms / drug therapy. Eye Neoplasms / pathology. Female. Humans. Limbus Corneae / drug effects. Limbus Corneae / pathology. Recurrence

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15126170.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


18. Schechter BA, Koreishi AF, Karp CL, Feuer W: Long-term follow-up of conjunctival and corneal intraepithelial neoplasia treated with topical interferon alfa-2b. Ophthalmology; 2008 Aug;115(8):1291-6, 1296.e1
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of conjunctival and corneal intraepithelial neoplasia treated with topical interferon alfa-2b.
  • OBJECTIVE: To evaluate the long-term recurrence rate (>1 year) of conjunctival and corneal intraepithelial neoplasia (CIN) treated with topical interferon alfa-2b.
  • PARTICIPANTS: Twenty-eight eyes of 26 patients from 2 institutions, treated between April 1997 and June 2005, with CIN lesions utilized topical interferon alfa-2b drops 4 times daily until clinical resolution was achieved.
  • MAIN OUTCOME MEASURES: All eyes were monitored for the possibility of recurrence with a minimum of 1-year follow-up from the time of documented clinical resolution.
  • RESULTS: Complete clinical resolution of the CIN lesions was achieved in 27 of the 28 eyes treated (96.4%).
  • One of the 28 eyes treated (3.6%) had only a partial response to treatment.
  • Side effects of treatment were limited to mild conjunctival hyperemia and follicular conjunctivitis in 3 patients (12%).
  • In all cases, there was total resolution of the side effects within 1 month after cessation of the medication.
  • CONCLUSIONS: In this group of patients with CIN lesions observed for >1 year, topical interferon alfa-2b was effective in treating lesions with minimal self-limited side effects.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy. Interferon-alpha / therapeutic use
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Recombinant Proteins. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18187195.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


19. Díaz-Valle D, Benítez-del-Castillo JM, Díaz-Valle T, Poza-Morales Y, Arteaga-Sánchez A: [Treatment with topical interferon alone in severe conjunctivo-corneal neoplasia]. Arch Soc Esp Oftalmol; 2005 Dec;80(12):729-32
MedlinePlus Health Information. consumer health - Corneal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment with topical interferon alone in severe conjunctivo-corneal neoplasia].
  • [Transliterated title] Interferón tópico como tratamiento único en un caso de neoplasia córneo-conjuntival severa.
  • The lesion was clinically diagnosed to be a conjunctival and corneal intraepithelial neoplasia (CIN).
  • Topical treatment with interferon alpha2b (INFalpha2b) four times daily was started and continued until the lesion had completely resolved at 4 months.
  • DISCUSSION: Topical INFalpha2b alone may be a safe and effective treatment of CIN instead of the other classic alternatives such as surgical excision with cryotherapy, which could induce the development of severe limbic deficiency in cases with extensive disease.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Interferon-alpha / administration & dosage
  • [MeSH-minor] Administration, Topical. Aged. Humans. Male. Recombinant Proteins. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16372217.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


20. Singh AD, Jacques R, Rundle PA, Rennie IG, Mudhar HS, Slater D: Neoadjuvant topical mitomycin C chemotherapy for conjunctival and corneal intraepithelial neoplasia. Eye (Lond); 2006 Sep;20(9):1092-4
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant topical mitomycin C chemotherapy for conjunctival and corneal intraepithelial neoplasia.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Cornea / pathology. Mitomycin / therapeutic use
  • [MeSH-minor] Aged. Humans. Male. Neoadjuvant Therapy. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16244642.001).
  • [ISSN] 0950-222X
  • [Journal-full-title] Eye (London, England)
  • [ISO-abbreviation] Eye (Lond)
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


21. Gabison EE, Labbé A, Brignole-Baudouin F, Nourry H, Putterman M, Malecaze F, Hoang-Xuan T, Baudouin C: Confocal biomicroscopy of corneal intraepithelial neoplasia regression following interferon alpha 2b treatment. Br J Ophthalmol; 2010 Jan;94(1):134-5
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Confocal biomicroscopy of corneal intraepithelial neoplasia regression following interferon alpha 2b treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy. Interferon-alpha / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20385531.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down






Advertisement